Combination Therapy With Erlotinib and Ramucirumab in a Patient With Epidermal Growth Factor Receptor Mutation Positive Lung Adenocarcinoma and Interstitial Pneumonia: A Case Report

Interstitial pneumonia often acts as a barrier to lung cancer treatment. We report the case of a 79-year-old man who was diagnosed with epidermal growth factor receptor (EGFR) mutation positive lung adenocarcinoma (T2aN0M0, stage ⅠB, EGFR exon 19 deletion), and was positive for anti-aminoacyl-tRNA s...

Full description

Saved in:
Bibliographic Details
Published in:Cureus 2023, Vol.15 (11), p.e49528-e49528
Main Authors: Tanaka, Shunya, Tsuji, Taisuke, Jinno, Kazuki, Matsumoto, Shoki
Format: Report
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page e49528
container_issue 11
container_start_page e49528
container_title Cureus
container_volume 15
creator Tanaka, Shunya
Tsuji, Taisuke
Jinno, Kazuki
Matsumoto, Shoki
description Interstitial pneumonia often acts as a barrier to lung cancer treatment. We report the case of a 79-year-old man who was diagnosed with epidermal growth factor receptor (EGFR) mutation positive lung adenocarcinoma (T2aN0M0, stage ⅠB, EGFR exon 19 deletion), and was positive for anti-aminoacyl-tRNA synthetase antibodies with interstitial pneumonia. Metastasis in the right seventh rib was detected three months after surgical resection and radiation therapy was initiated. As recurrence was observed at both ends of the radiation field five months later, combination chemotherapy with erlotinib and ramucirumab was initiated. Approximately one year has passed since the start initiation of treatment, and acute exacerbation of interstitial pneumonia has not been observed during the follow-up period observation. The tumor has remained stable, indicating stable disease.
doi_str_mv 10.7759/cureus.49528
format report
fullrecord <record><control><sourceid>proquest</sourceid><recordid>TN_cdi_proquest_miscellaneous_2908125000</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2908125000</sourcerecordid><originalsourceid>FETCH-proquest_miscellaneous_29081250003</originalsourceid><addsrcrecordid>eNqVj81KA0EQhAdRMGhuPkAfvSTOrom76y2ERAWFJQQ8hs5sa1p2etb5UXww389Vc_DqqYri6ypaqbNMj4tiWl2Y5CmF8aSa5uWBGuTZVTkqs3Jy-Mcfq2EIL1rrTBe5LvRAfc6d3bJgZCew3pHH7gMeOe5g4VsXWXgLKA2s0CbDPlncAgsg1P0JSdyzHTfkLbZw4917HyzRROdhRYa6b_OQ4u9E7QJHfiO4T_IMs4bEGfSGxVn8GbqTSD7EHurbaqFknTBewwzmGKhv7JyPp-roCdtAw72eqPPlYj2_HXXevSYKcWM5GGpbFHIpbPJKl1k-7R-__Af6BfaPb3o</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>report</recordtype><pqid>2908125000</pqid></control><display><type>report</type><title>Combination Therapy With Erlotinib and Ramucirumab in a Patient With Epidermal Growth Factor Receptor Mutation Positive Lung Adenocarcinoma and Interstitial Pneumonia: A Case Report</title><source>Open Access: PubMed Central</source><source>Publicly Available Content Database (Proquest) (PQ_SDU_P3)</source><creator>Tanaka, Shunya ; Tsuji, Taisuke ; Jinno, Kazuki ; Matsumoto, Shoki</creator><creatorcontrib>Tanaka, Shunya ; Tsuji, Taisuke ; Jinno, Kazuki ; Matsumoto, Shoki</creatorcontrib><description>Interstitial pneumonia often acts as a barrier to lung cancer treatment. We report the case of a 79-year-old man who was diagnosed with epidermal growth factor receptor (EGFR) mutation positive lung adenocarcinoma (T2aN0M0, stage ⅠB, EGFR exon 19 deletion), and was positive for anti-aminoacyl-tRNA synthetase antibodies with interstitial pneumonia. Metastasis in the right seventh rib was detected three months after surgical resection and radiation therapy was initiated. As recurrence was observed at both ends of the radiation field five months later, combination chemotherapy with erlotinib and ramucirumab was initiated. Approximately one year has passed since the start initiation of treatment, and acute exacerbation of interstitial pneumonia has not been observed during the follow-up period observation. The tumor has remained stable, indicating stable disease.</description><identifier>ISSN: 2168-8184</identifier><identifier>EISSN: 2168-8184</identifier><identifier>DOI: 10.7759/cureus.49528</identifier><language>eng</language><ispartof>Cureus, 2023, Vol.15 (11), p.e49528-e49528</ispartof><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>780,784,4490,27925,37013</link.rule.ids></links><search><creatorcontrib>Tanaka, Shunya</creatorcontrib><creatorcontrib>Tsuji, Taisuke</creatorcontrib><creatorcontrib>Jinno, Kazuki</creatorcontrib><creatorcontrib>Matsumoto, Shoki</creatorcontrib><title>Combination Therapy With Erlotinib and Ramucirumab in a Patient With Epidermal Growth Factor Receptor Mutation Positive Lung Adenocarcinoma and Interstitial Pneumonia: A Case Report</title><title>Cureus</title><description>Interstitial pneumonia often acts as a barrier to lung cancer treatment. We report the case of a 79-year-old man who was diagnosed with epidermal growth factor receptor (EGFR) mutation positive lung adenocarcinoma (T2aN0M0, stage ⅠB, EGFR exon 19 deletion), and was positive for anti-aminoacyl-tRNA synthetase antibodies with interstitial pneumonia. Metastasis in the right seventh rib was detected three months after surgical resection and radiation therapy was initiated. As recurrence was observed at both ends of the radiation field five months later, combination chemotherapy with erlotinib and ramucirumab was initiated. Approximately one year has passed since the start initiation of treatment, and acute exacerbation of interstitial pneumonia has not been observed during the follow-up period observation. The tumor has remained stable, indicating stable disease.</description><issn>2168-8184</issn><issn>2168-8184</issn><fulltext>true</fulltext><rsrctype>report</rsrctype><creationdate>2023</creationdate><recordtype>report</recordtype><recordid>eNqVj81KA0EQhAdRMGhuPkAfvSTOrom76y2ERAWFJQQ8hs5sa1p2etb5UXww389Vc_DqqYri6ypaqbNMj4tiWl2Y5CmF8aSa5uWBGuTZVTkqs3Jy-Mcfq2EIL1rrTBe5LvRAfc6d3bJgZCew3pHH7gMeOe5g4VsXWXgLKA2s0CbDPlncAgsg1P0JSdyzHTfkLbZw4917HyzRROdhRYa6b_OQ4u9E7QJHfiO4T_IMs4bEGfSGxVn8GbqTSD7EHurbaqFknTBewwzmGKhv7JyPp-roCdtAw72eqPPlYj2_HXXevSYKcWM5GGpbFHIpbPJKl1k-7R-__Af6BfaPb3o</recordid><startdate>20231101</startdate><enddate>20231101</enddate><creator>Tanaka, Shunya</creator><creator>Tsuji, Taisuke</creator><creator>Jinno, Kazuki</creator><creator>Matsumoto, Shoki</creator><scope>7X8</scope></search><sort><creationdate>20231101</creationdate><title>Combination Therapy With Erlotinib and Ramucirumab in a Patient With Epidermal Growth Factor Receptor Mutation Positive Lung Adenocarcinoma and Interstitial Pneumonia: A Case Report</title><author>Tanaka, Shunya ; Tsuji, Taisuke ; Jinno, Kazuki ; Matsumoto, Shoki</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-proquest_miscellaneous_29081250003</frbrgroupid><rsrctype>reports</rsrctype><prefilter>reports</prefilter><language>eng</language><creationdate>2023</creationdate><toplevel>online_resources</toplevel><creatorcontrib>Tanaka, Shunya</creatorcontrib><creatorcontrib>Tsuji, Taisuke</creatorcontrib><creatorcontrib>Jinno, Kazuki</creatorcontrib><creatorcontrib>Matsumoto, Shoki</creatorcontrib><collection>MEDLINE - Academic</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Tanaka, Shunya</au><au>Tsuji, Taisuke</au><au>Jinno, Kazuki</au><au>Matsumoto, Shoki</au><format>book</format><genre>unknown</genre><ristype>RPRT</ristype><atitle>Combination Therapy With Erlotinib and Ramucirumab in a Patient With Epidermal Growth Factor Receptor Mutation Positive Lung Adenocarcinoma and Interstitial Pneumonia: A Case Report</atitle><jtitle>Cureus</jtitle><date>2023-11-01</date><risdate>2023</risdate><volume>15</volume><issue>11</issue><spage>e49528</spage><epage>e49528</epage><pages>e49528-e49528</pages><issn>2168-8184</issn><eissn>2168-8184</eissn><abstract>Interstitial pneumonia often acts as a barrier to lung cancer treatment. We report the case of a 79-year-old man who was diagnosed with epidermal growth factor receptor (EGFR) mutation positive lung adenocarcinoma (T2aN0M0, stage ⅠB, EGFR exon 19 deletion), and was positive for anti-aminoacyl-tRNA synthetase antibodies with interstitial pneumonia. Metastasis in the right seventh rib was detected three months after surgical resection and radiation therapy was initiated. As recurrence was observed at both ends of the radiation field five months later, combination chemotherapy with erlotinib and ramucirumab was initiated. Approximately one year has passed since the start initiation of treatment, and acute exacerbation of interstitial pneumonia has not been observed during the follow-up period observation. The tumor has remained stable, indicating stable disease.</abstract><doi>10.7759/cureus.49528</doi></addata></record>
fulltext fulltext
identifier ISSN: 2168-8184
ispartof Cureus, 2023, Vol.15 (11), p.e49528-e49528
issn 2168-8184
2168-8184
language eng
recordid cdi_proquest_miscellaneous_2908125000
source Open Access: PubMed Central; Publicly Available Content Database (Proquest) (PQ_SDU_P3)
title Combination Therapy With Erlotinib and Ramucirumab in a Patient With Epidermal Growth Factor Receptor Mutation Positive Lung Adenocarcinoma and Interstitial Pneumonia: A Case Report
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T11%3A47%3A16IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest&rft_val_fmt=info:ofi/fmt:kev:mtx:book&rft.genre=unknown&rft.atitle=Combination%20Therapy%20With%20Erlotinib%20and%20Ramucirumab%20in%20a%20Patient%20With%20Epidermal%20Growth%20Factor%20Receptor%20Mutation%20Positive%20Lung%20Adenocarcinoma%20and%20Interstitial%20Pneumonia:%20A%20Case%20Report&rft.jtitle=Cureus&rft.au=Tanaka,%20Shunya&rft.date=2023-11-01&rft.volume=15&rft.issue=11&rft.spage=e49528&rft.epage=e49528&rft.pages=e49528-e49528&rft.issn=2168-8184&rft.eissn=2168-8184&rft_id=info:doi/10.7759/cureus.49528&rft_dat=%3Cproquest%3E2908125000%3C/proquest%3E%3Cgrp_id%3Ecdi_FETCH-proquest_miscellaneous_29081250003%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2908125000&rft_id=info:pmid/&rfr_iscdi=true